Article Figures & Data
Figures
- FIGURE 1.
Box plot of SUVmax from malignant (left) and normal (right) intraprostatic tissue.
- FIGURE 2.
Box plot of SUVmax according to GS in biopsy (A) and d’Amico classification (B).
- FIGURE 3.
Box plot of SUVmax according to ungrouped GS in biopsy (A) and to International Society of Urologic Pathologists (ISUP) grade in biopsy (B).
- FIGURE 4.
Box plot of SUVmax of GS (grouped) after prostatectomy.
- FIGURE 5.
Different PSMA tracer uptake according to GS: 1 patient with GS 6 prostate cancer and SUVmax of 7.33 (A) compared with a GS 9 tumor and SUVmax of 16.64 (B).
- FIGURE 6.
Relevant data for intraprostatic boost during radiotherapy: MRI of prostate with apparent diffusion coefficient sequence (A), PSMA tracer uptake in PSMA PET/CT (B), and radiation plan with irradiation of prostate and simultaneous integrated boost according to pretreatment imaging (C).
Tables
Characteristic All patients (n = 104) Median age (y) 67.4 (range, 38–84) Clinical tumor stage T1a — T1b — T1c 39 T2a 1 T2b 1 T2c 25 T3a 7 T3b 26 T4 5 N0 72 N1 32 M0 82 M1a 3 M1b 17 M1c 2 GS (biopsy) 6 15 7a 24 7b 16 8 19 9 26 10 4 Current PSA <10 ng/mL 35 10–20 ng/mL 30 >20 ng/mL 38 Unknown 1 d’Amico score (21) Low risk 6 Intermediate risk 17 High risk 81 Clinical parameter Median Mean SUVmax SD P Current PSA (n = 103) <0.001 10 5.98 8.55 5.88 10–20 7.94 14.97 16.20 20 14.77 19.47 15.47 GS in biopsy (grouped; n = 104) <0.001 6–7 6.28 9.88 10.49 8–10 16.29 19.61 15.44 GS in biopsy (n = 104) <0.001 6 4.62 6.74 6.10 7a 5.56 9.74 13.47 7b 11.56 13.04 7.89 8 13.94 16.4 10.75 9 16.99 22.16 18.46 10 16.88 18.30 12.45 d’Amico score (n = 104) Grouped <0.001 Low/intermediate risk 5.79 6.72 3.95 High risk 12.27 16.67 14.88 Ungrouped <0.001 Low risk 5.12 5.97 3.69 Intermediate risk 5.79 6.98 4.11 High risk 12.27 16.67 14.88 GS Median Mean SUVmax SD P In MR-guided biopsy (grouped; n = 50) 0.004 7 7.59 11.24 12.9 8–10 13.12 19.45 17.24 After prostatectomy (grouped; n = 28) 0.14 7 8.32 14.1 11.07 8–10 16.64 20.41 11.51
Jump to section
Related Articles
Cited By...
- 68Ga-PSMA PET/CT Combined with PET/Ultrasound-Guided Prostate Biopsy Can Diagnose Clinically Significant Prostate Cancer in Men with Previous Negative Biopsy Results
- Diagnostic Value of 68Ga-PSMA PET/CT for Detection of Phosphatase and Tensin Homolog Expression in Prostate Cancer: A Pilot Study
- Patients Resistant Against PSMA-Targeting {alpha}-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated Genes
- Prospective Evaluation of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer in an Academic Center: A Focus on Disease Localization and Changes in Management
- 68Ga-PSMA-11 PET/MR Detects Local Recurrence Occult on mpMRI in Prostate Cancer Patients After HIFU
- 68Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients
- Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT